Submitted: 31 Jul 2022
Revision: 27 Nov 2022
Accepted: 13 Dec 2022
ePublished: 28 Jun 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Avicenna J Med Biochem. 2023;11(1): 46-54.
doi: 10.34172/ajmb.2023.2376
  Abstract View: 809
  PDF Download: 408

Original Article

Efficacy of Kabab Chini (Piper cubeba Linn) in Chronic Kidney Disease: A Randomized Controlled Clinical Trial

Khan Ishrat Jahan 1* ORCID logo, Mansoor Ahmed Siddiqui 1, Mohammed Aleemuddin Quamri 1, Hamiduddin Hamiduddin 2, Siddiqui Aafreen 1

1 Department of Moalajat (Medicine), National Institute of Unani Medicine, Bengaluru, Karnataka, India-560091
2 Department of Ilmul Saidla (Pharmacy), National Institute of Unani Medicine, Bengaluru, Karnataka, India-560091
*Corresponding Author: Khan Ishrat Jahan, Email: khanishrat369@gmail.com


Background: Chronic Kidney Disease (CKD) is a major public health problem with a global prevalence of approximately 13% with the majority stage 3 and is a global threat to health in general and for developing countries in particular, because therapy is expensive and life-long. In India 90% patients cannot afford the cost of treatment for CKD, over 1 million people worldwide alive on dialysis or with a functioning graft. It is the need of the time to find alternate treatment to control CKD. Hence this study aims to evaluate clinically the efficacy of Kabab Chini (Piper cubeba) in CKD stage 1-3 and also to compare the effectiveness of the marketed drug NEERI KFT® scientifically.

Objectives: To evaluate the efficacy of Kabab Chini (Piper cubeba) in chronic kidney disease (CKD) stage 1-3 patients.

Methods: In this open-labeled randomized controlled clinical trial, 30 participants, randomly allocated to two groups, received 4 g of either sufoof (powder) of Kabab Chini in a divided dose thrice a day (Test group, n=15) or 10 mL of Syrup NEERI-KFT three times a day (Control group, n=15) for 42 days. The objective parameters were serum creatinine, blood urea (BU), estimated glomerular filtration rate (eGFR), and urine routine and microscopy, whereas subjective parameters were anorexia, easy fatigability, and edema. Objective and subjective parameters were assessed at weekly follow-ups, and safety parameters were assessed at baseline and after 42 days.

Results: Intragroup data suggest significant improvements in anorexia, easy fatigability, and eGFR in both groups (P=0.001), whereas the intragroup serum creatinine value was significantly reduced in the test (P=0.028) and control (P=0.256) groups. No significant improvement in edema and albumin was observed in both groups (P>0.05). The test drug was found to be tolerable with no adverse effects.

Conclusion: The results of the present study revealed that Kabab Chini is effective in reducing serum creatinine, eGFR, anorexia, and easy fatigability moderately superior to Syrup NEERI-KFT® with respect to efficacy without any adverse effect and accepted alternate hypothesis.

Please cite this article as follows: Jahan KI, Siddiqui MA, Quamri MA, Hamiduddin, Aafreen S. Efficacy of Kabab Chini (Piper cubeba linn) in chronic kidney disease: a randomized controlled clinical trial. Avicenna J Med Biochem. 2023; 11(1):46-54. doi:10.34172/ajmb.2023.2376
First Name
Last Name
Email Address
Security code

Abstract View: 810

Your browser does not support the canvas element.

PDF Download: 408

Your browser does not support the canvas element.